Why the study?
Cardiogenic shock complicating mitral valve diseases presents a management dilemma with high mortality and limited evidence for specific interventions.
A multidisciplinary approach utilizing mechanical circulatory support and minimally invasive transcatheter therapies is a viable treatment strategy for critically ill patients with cardiogenic shock secondary to mitral valve disease who are poor surgical candidates.
Answers are grounded in this paper and cite their sources.
Cardiogenic shock with mitral valve disease complicates management; leaves open optimal strategies pending prospective data.
Despite advances in the field of cardiology, cardiogenic shock (CS) remains a management dilemma with a high mortality rate. While most cases of CS are secondary to acute coronary syndrome (ACS), approximately one-fifth can be attributed to delayed mechanical complications of ACS, such as arrhythmia, cardiac tamponade, or valvular heart diseases. The coexistence of CS and mitral valve diseases (MVDs) further complicates clinical presentation, diagnosis, and management strategies. Surgical interventions are considered the gold standard for managing MVDs in the context of CS. However, these patients are often at extreme surgical risk and may not achieve favorable outcomes. Catheter-based interventions have garnered increasing interest, but despite their promising results, most trials have excluded patients in unstable or critical conditions. Pharmacological and mechanical circulatory support provide a bridge to definitive transcatheter or surgical intervention.
No takes yet. Share an insight, caveat, or question.
Ashraf O. E. Ahmed (2024) conducted a review in Cardiogenic shock in mitral valve diseases. Pharmacological, mechanical circulatory support, and transcatheter or surgical interventions was evaluated.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: